$798 Million is the total value of Rhenman & Partners Asset Management AB's 93 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DVAX | Dynavax Technologies Corp | $4,413,000 | -10.4% | 1,234,335 | 0.0% | 0.55% | +2.0% | |
| AIMT | Aimmune Therapeutics Inc Reg | $3,124,000 | +0.6% | 149,201 | 0.0% | 0.39% | +14.6% | |
| XLRN | Acceleron Pharma Inc Reg | $2,766,000 | -3.8% | 70,000 | 0.0% | 0.35% | +9.5% | |
| PIRS | Pieris Pharmaceuticals Inc Reg | $1,023,000 | -27.4% | 300,000 | 0.0% | 0.13% | -17.4% | |
| ACHN | Achillion Pharmaceuticals Inc | $1,000,000 | +34.2% | 277,800 | 0.0% | 0.12% | +52.4% | |
| ADVM | Adverum Biotechnologies Inc | $652,000 | -54.2% | 119,673 | 0.0% | 0.08% | -47.8% | |
| CVX | Chevron Corp | $353,000 | -4.6% | 2,974 | 0.0% | 0.04% | +7.3% | |
| BUD | Anheuser-Busch InBev SA ADR spons repr 1 Sharesponsored adr | $324,000 | +7.3% | 3,409 | 0.0% | 0.04% | +24.2% | |
| IBM | IBM Corp | $322,000 | +5.6% | 2,215 | 0.0% | 0.04% | +17.6% | |
| JPM | JPMorgan Chase & Co | $291,000 | +5.4% | 2,472 | 0.0% | 0.04% | +20.0% | |
| DIS | The Walt Disney Co | $271,000 | -6.9% | 2,083 | 0.0% | 0.03% | +6.2% | |
| SNSS | Sunesis Pharmaceuticals Inc Reg | $272,000 | -0.7% | 377,244 | 0.0% | 0.03% | +13.3% | |
| XOM | Exxon Mobil Corp | $272,000 | -7.8% | 3,854 | 0.0% | 0.03% | +6.2% | |
| WFC | Wells Fargo & Co | $266,000 | +6.8% | 5,272 | 0.0% | 0.03% | +22.2% | |
| F | Ford Motor Co | $267,000 | -10.4% | 29,164 | 0.0% | 0.03% | 0.0% | |
| QCOM | Qualcomm Inc | $259,000 | +0.4% | 3,391 | 0.0% | 0.03% | +14.3% | |
| JHG | Janus Henderson Group Plc Reg | $239,000 | +4.8% | 10,645 | 0.0% | 0.03% | +20.0% | |
| MSFT | Microsoft Corp | $213,000 | +3.9% | 1,532 | 0.0% | 0.03% | +17.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-10-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.